About Double C2-like domain-containing protein beta
Double C2-like domain-containing protein beta (DOC2B) is a protein
from Homo sapiens identified by UniProt accession
Q14184, 412 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | Double C2-like domain-containing protein beta |
| UniProt accession | Q14184 |
| Gene | DOC2B |
| Organism | Homo sapiens |
| Length | 412 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (35)
Diseases linked to this target (Open Targets).
- primary ovarian insufficiency · score 0.12
- IGF-1 measurement · score 0.06
- type 1 diabetes mellitus · score 0.04
- neoplasm · score 0.03
- ulcerative colitis · score 0.03
- drug use measurement · score 0.02
- glioblastoma multiforme · score 0.02
- type 2 diabetes mellitus · score 0.02
- calf circumference measurement · score 0.01
- rosacea · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14184-F1 | alphafold | PREDICTED | 78.20 | — |
Amino-acid sequence (412 residues)
MTLRRRGEKA TISIQEHMAI DVCPGPIRPI KQISDYFPRF PRGLPPDAGP RAAAPPDAPA RPAVAGAGRR SPSDGAREDD EDVDQLFGAY GSSPGPSPGP SPARPPAKPP EDEPDADGYE SDDCTALGTL DFSLLYDQEN NALHCTITKA KGLKPMDHNG LADPYVKLHL LPGASKANKL RTKTLRNTLN PTWNETLTYY GITDEDMIRK TLRISVCDED KFRHNEFIGE TRVPLKKLKP NHTKTFSICL EKQLPVDKTE DKSLEERGRI LISLKYSSQK QGLLVGIVRC AHLAAMDANG YSDPYVKTYL RPDVDKKSKH KTAVKKKTLN PEFNEEFCYE IKHGDLAKKS LEVTVWDYDI GKSNDFIGGV VLGIHAKGER LKHWFDCLKN KDKRIERWHT LTSELPGAVL SD
Explore Double C2-like domain-containing protein beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets